Clinical trialNCT07049055RecruitingPhase 1/PHASE2Interventional

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

SponsorEngeneic Pty LimitedEnrollment144PDAC - Pancreatic Ductal AdenocarcinomaPancreatic Cancer, Metastatic

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Dr Himanshu Brahmbhatt, Ph.D
Engeneic Pty Limited
Study Director
clinicaltrials.gov ↗
Dr Jennifer MacDiarmid, Ph.D
Engeneic Pty Limited
Study Director
clinicaltrials.gov ↗
Dr Linda Y.Wu, MD
Columbia University Medical Center/ Herbert Irving Pavilion
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Chan Soon-Shiong Institute for Medicine
El Segundo, California, United States
Active, not recruiting
Atlantic Health
Summit, New Jersey, United States
Usman Shah, MD
Recruiting
Columbia University Irving Medical Center
New York, New York, United States
Dr Linda Y.Wu, MD
Recruiting
Taylor Cancer Center
Maumee, Ohio, United States
Dr John Nemunaitis, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

E-EDV-D682EDV-GCGemcitabine →Paclitaxel →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Jan 2026
Primary completion: 30 Sept 2028
Completion: 30 Sept 2028
Last update posted: 27 Feb 2026
Registered enrollment: 144
Registry id: NCT07049055

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.